Arca
Skip to content
Tools
Tools

SMN1, SMN2: Survival motor neuron protein

Protein in Homo sapiens that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on SMN1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Other 1

Approved1

  • Onasemnogene abeparvovec

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        Onasemnogene abeparvovecApprovedNovartis PharmaceuticalsGeneExogenous geneSurvival motor neuron protein exogenous gene12

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Registry of Cases of Spinal Muscular AtrophyOnasemnogene abeparvovec—RecruitingSt. Jude Children's Research HospitalSep 4, 2026
        A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy PatientsOnasemnogene abeparvovec—RecruitingNovartis PharmaceuticalsAug 17, 2026
        A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi ArabiaOnasemnogene abeparvovec—Not yet recruitingNovartis PharmaceuticalsJul 30, 2026
        ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)Onasemnogene abeparvovecPhase 4RecruitingNovartis PharmaceuticalsMar 4, 2026
        A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene AbeparvovecOnasemnogene abeparvovecPhase 3RecruitingBiogenMar 3, 2026
        A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular AtrophyOnasemnogene abeparvovecPhase 2RecruitingScholar Rock, Inc.Jul 2, 2025
        Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring TherapyOnasemnogene abeparvovecNot applicableRecruitingHospices Civils de LyonMar 20, 2024
        A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With ZolgensmaOnasemnogene abeparvovec—RecruitingNovartis PharmaceuticalsAug 31, 2023

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1293232, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.